- 2022.09.13
Lemzoparlimab Data Readout at ESMO 2022
Presentation details
Abstract Title: Lemzoparlimab, a Differentiated Anti-CD47 Monoclonal Antibody, in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): Initial Clinical Results
Abstract #: 3823
First author: Prof. Zhijian Xiao, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences
Session: Proffered Paper
Date and Time: Tuesday, September 13, 2022